Advanced search
Publication Cover
Gut Microbes Volume 5, 2014 - Issue 6
Submit an article Journal homepage
2,532
Views
29
CrossRef citations to date
0
Altmetric
REVIEWS

The potential for emerging therapeutic options for Clostridium difficile infection

Harsh MathurSchool of Microbiology; University College Cork; Cork, Ireland;Teagasc Food Research Center; Moorepark; Fermoy, Ireland
,
Mary C ReaTeagasc Food Research Center; Moorepark; Fermoy, Ireland;Alimentary Pharmabiotic Center; University College Cork; Cork, Ireland
,
Paul D CotterTeagasc Food Research Center; Moorepark; Fermoy, Ireland;Alimentary Pharmabiotic Center; University College Cork; Cork, IrelandCorrespondence[email protected] [email protected]
,
R Paul RossAlimentary Pharmabiotic Center; University College Cork; Cork, Ireland;College of Science; Engineering and Food Science; University College Cork; Cork, Ireland
&
Colin HillSchool of Microbiology; University College Cork; Cork, Ireland;Alimentary Pharmabiotic Center; University College Cork; Cork, IrelandCorrespondence[email protected] [email protected]
Pages 696-710 | Received 12 May 2014, Accepted 13 Oct 2014, Published online: 26 Jan 2015

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Vo Van Giau, Hyon Lee, Seong Soo A An & John Hulme. (2019) Recent advances in the treatment of C. difficile using biotherapeutic agents. Infection and Drug Resistance 12, pages 1597-1615.
Read now
Zhong Peng, Lifen Ling, Charles W. Stratton, Chunhui Li, Christopher R. Polage, Bin Wu & Yi-Wei Tang. (2018) Advances in the diagnosis and treatment of Clostridium difficile infections. Emerging Microbes & Infections 7:1, pages 1-13.
Read now
Omar Abughanimeh, Ayman Qasrawi, Osama Kaddourah, Laith Al Momani & Mouhanna Abu Ghanimeh. (2018) Clostridium difficile infection in oncology patients: epidemiology, pathophysiology, risk factors, diagnosis, and treatment. Hospital Practice 46:5, pages 266-277.
Read now
Christine SM Lau & Ronald S Chamberlain. (2016) Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. International Journal of General Medicine 9, pages 27-37.
Read now
Greg Hussack & Jamshid Tanha. (2016) An update on antibody-based immunotherapies for Clostridium difficile infection. Clinical and Experimental Gastroenterology 9, pages 209-224.
Read now

Articles from other publishers (24)

Muhammad Waqas, Khadija Mohib, Aniqa Saleem, Mahak LNU, Sabeen Arjumand, Hafiz Habib Ur Rehman Khalil, Rukhshanda Nosheen, Sharmeen Abbas, Kanza M Maqsood & Kiran Abbas. (2022) Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection. Cureus.
Crossref
Atieh Darbandi, Arezoo Asadi, Marzieh Mahdizade Ari, Elnaz Ohadi, Malihe Talebi, Masoume Halaj Zadeh, Amir Darb Emamie, Roya Ghanavati & Maryam Kakanj. (2021) Bacteriocins: Properties and potential use as antimicrobials. Journal of Clinical Laboratory Analysis 36:1.
Crossref
Svetoslav D. Todorov, Hye-Ji Kang, Iskra V. Ivanova & Wilhelm H. Holzapfel. (2020) Bacteriocins From LAB and Other Alternative Approaches for the Control of Clostridium and Clostridiodes Related Gastrointestinal Colitis. Frontiers in Bioengineering and Biotechnology 8.
Crossref
Jennifer M. Auchtung, Eva C. Preisner, James Collins, Armando I. Lerma & Robert A. Britton. (2020) Identification of Simplified Microbial Communities That Inhibit Clostridioides difficile Infection through Dilution/Extinction. mSphere 5:4.
Crossref
José Millán Oñate-Gutiérrez, Janier Segura, Adriana Correa, Erika Cantor & María Virginia Villegas. (2019) Infección por Clostridium difficile: descripción de las cepas NAP1/027 y de otros serotipos en un centro de alta complejidad de Cali, Colombia, 2012-2015. Biomédica 39, pages 63-70.
Crossref
T. J. De Wolfe, S. Eggers, A. K. Barker, A. E. Kates, K. A. Dill-McFarland, G. Suen & N. Safdar. (2018) Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection. PLOS ONE 13:9, pages e0204253.
Crossref
Nicola Petrosillo, Guido Granata & Maria Adriana Cataldo. (2018) Novel Antimicrobials for the Treatment of Clostridium difficile Infection. Frontiers in Medicine 5.
Crossref
Duolong Zhu, Joseph A. Sorg & Xingmin Sun. (2018) Clostridioides difficile Biology: Sporulation, Germination, and Corresponding Therapies for C. difficile Infection. Frontiers in Cellular and Infection Microbiology 8.
Crossref
James Collins & Jennifer M. Auchtung. 2018. Bugs as Drugs. Bugs as Drugs 267 289 .
Niloufar Roshan, Katherine A. Hammer & Thomas V. Riley. (2018) Non-conventional antimicrobial and alternative therapies for the treatment of Clostridium difficile infection. Anaerobe 49, pages 103-111.
Crossref
Lorena Valdés-Varela, Miguel Gueimonde & Patricia Ruas-Madiedo. 2018. Updates on Clostridium difficile in Europe. Updates on Clostridium difficile in Europe 161 176 .
James Collins & Jennifer M. Auchtung. (2017) Control of Clostridium difficile Infection by Defined Microbial Communities . Microbiology Spectrum 5:5.
Crossref
Fernando Santos-Beneit, Mar?a Ord??ez-Robles & Juan F. Mart?n. (2017) Glycopeptide resistance: Links with inorganic phosphate metabolism and cell envelope stress. Biochemical Pharmacology 133, pages 74-85.
Crossref
Xin Tao, Jason M. Franasiak, Yiping Zhan, Richard T. ScottIIIIII, Jessica Rajchel, Jenna Bedard, Robert NewbyJr.Jr., Richard T. Scott, Nathan R. Treff & Tinchun Chu. (2017) Characterizing the endometrial microbiome by analyzing the ultra-low bacteria from embryo transfer catheter tips in IVF cycles: Next generation sequencing (NGS) analysis of the 16S ribosomal gene. Human Microbiome Journal 3, pages 15-21.
Crossref
Khee-Siang Chan, Wen-Ying Lee & Wen-Liang Yu. (2016) Coexisting cytomegalovirus infection in immunocompetent patients with Clostridium difficile colitis. Journal of Microbiology, Immunology and Infection 49:6, pages 829-836.
Crossref
Aleksandar Cvetkovic, Danijela Cvetkovic, Vladislava Stojic & Nebojsa Zdravkovic. (2016) Length of Hospital Stay and Bed Occupancy Rates in Former Yugoslav Republics 1989–2015. Frontiers in Pharmacology 7.
Crossref
Eamonn Culligan & Roy Sleator. (2016) Advances in the Microbiome: Applications to Clostridium difficile Infection. Journal of Clinical Medicine 5:9, pages 83.
Crossref
Aabha Gupta, Santosh Kumar Tiwari, Victoria Netrebov & Michael L. Chikindas. (2016) Biochemical Properties and Mechanism of Action of Enterocin LD3 Purified from Enterococcus hirae LD3. Probiotics and Antimicrobial Proteins 8:3, pages 161-169.
Crossref
Jonathan M. Pitt, Marie Vétizou, Romain Daillère, María Paula Roberti, Takahiro Yamazaki, Bertrand Routy, Patricia Lepage, Ivo Gomperts Boneca, Mathias Chamaillard, Guido Kroemer & Laurence Zitvogel. (2016) Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity 44:6, pages 1255-1269.
Crossref
Lorena Valdés-Varela, Marta Alonso-Guervos, Olivia García-Suárez, Miguel Gueimonde & Patricia Ruas-Madiedo. (2016) Screening of Bifidobacteria and Lactobacilli Able to Antagonize the Cytotoxic Effect of Clostridium difficile upon Intestinal Epithelial HT29 Monolayer. Frontiers in Microbiology 7.
Crossref
Lorena Valdés, Miguel Gueimonde & Patricia Ruas-Madiedo. (2015) Monitoring in real time the cytotoxic effect of Clostridium difficile upon the intestinal epithelial cell line HT29. Journal of Microbiological Methods 119, pages 66-73.
Crossref
Jennifer M. Colquhoun, Rachel A. F. Wozniak & Paul M. Dunman. (2015) Clinically Relevant Growth Conditions Alter Acinetobacter baumannii Antibiotic Susceptibility and Promote Identification of Novel Antibacterial Agents. PLOS ONE 10:11, pages e0143033.
Crossref
Silvia Melgar & Max Nieuwdorp. (2015) Are Proton Pump Inhibitors Affecting Intestinal Microbiota Health?. Gastroenterology 149:4, pages 848-850.
Crossref
Carl N. Kraus, Matthew W. Lyerly & Robert J. Carman. (2015) Ambush of Clostridium difficile Spores by Ramoplanin: Activity in an In Vitro Model . Antimicrobial Agents and Chemotherapy 59:5, pages 2525-2530.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.